leadf
logo-loader
viewShield Therapeutics PLC

Shield Therapeutics - Block Listing 6 Monthly Return

RNS Number : 6269A
Shield Therapeutics PLC
30 September 2020
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Block Listing 6 Monthly Return

 

Date: 30 September 2020

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics Retention Share Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

54,219

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

54,219

         

 

Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics plc 2016 Company Share Option Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

388,079

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

388,079

         

 

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

The Shield Therapeutics plc 2016 Long Term Incentive Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

171,883

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

171,883 

         

 

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention and Performance Share Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

1,885,819

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,885,819

         

  

Name of contact:

Lucy Huntington-Bailey

Telephone number of contact:

+44 (0) 191 511 8500

 

  

 

 

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Tim Watts, Chief Executive Officer

+44 (0)20 7186 8500

Lucy Huntington-Bailey, General Counsel and Company Secretary

+44 (0) 19 1511 8500

 

 

 

Nominated Advisor and Broker

 

Peel Hunt LLP

 

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd     

Geoff Nash/Matt Radley/Alice Lane                                             

 

 

+44 (0)20 7220 0500

 

 

 Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREAANEDFXEEFA

Quick facts: Shield Therapeutics PLC

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

11 hours, 16 minutes ago

6 min read